Both plasmapheresis and EBOO ozone therapy are blood-level interventions — but they work in fundamentally different ways. Understanding the difference helps you and your physician choose the right protocol.
Side-by-Side
Mechanism
EBOO: oxidizes pathogens and filters lipid peroxides while leaving plasma intact. Plasmapheresis: removes the plasma entirely and replaces it with clean fluid.
What's Removed
EBOO targets pathogens, biofilms, and oxidized lipids. Plasmapheresis additionally removes autoantibodies, cytokines, immune complexes, and protein-bound toxins.
Best For
EBOO: brain fog, sluggish methylation, chronic infection, longevity maintenance. Plasmapheresis: autoimmunity, severe neuro-inflammation, post-pharmaceutical detox, and biological age reset.
Used Together
At Sanctuary Tulum, EBOO often precedes plasmapheresis to reduce oxidative load before the deeper reset.
Clinical Screening Before Any Session
Every prospective guest at Sanctuary Tulum completes a confidential clinical intake and full medical screening before any plasmapheresis vs EBOO session is scheduled. The intake reviews cardiovascular status, kidney and liver function, current medications, coagulation history, and any recent infections. Guests currently prescribed anticoagulants, immunosuppressants, or SSRIs are reviewed on a case-by-case basis with their treating physician before a session is planned.1 The team never advises anyone to discontinue prescribed medication on their own.
On-Site Medical Oversight
A physician is on site during every session, supported by registered nurses and IV therapy specialists. Vital signs — blood pressure, oxygen saturation, and cardiac rhythm where clinically indicated — are monitored continuously across the session, with emergency medications and airway equipment on hand.2 Credentialing detail lives on the Medical Review Board page, and a broader description of the safety approach is available on the safest psychedelic facility page. Guests are encouraged to review both before deciding whether the program fits them.
How This Fits the Wider Program
Therapeutic plasma exchange sits inside a broader biological and neurological protocol at Sanctuary Tulum rather than being offered as a standalone service. That means medical stabilization first, then a physician-scheduled combination of NAD+ IV therapy, HBOT, targeted nutrition, and — where clinically appropriate — medically supervised ibogaine treatment, ayahuasca ceremonies, or psilocybin therapy. The full framework is described in the proprietary Pouyan Method™. The exact sequence is individual and set by the medical team after intake — one guest's plan rarely looks identical to another's.
Honest Limits of the Evidence
Published research on plasmapheresis vs EBOO for the indications discussed here is still evolving. Therapeutic apheresis is well established for specific autoimmune and neurologic conditions in mainstream medicine,3 and ozone therapies have a longer clinical history in parts of Europe than in the United States. For broader wellness applications the evidence base is smaller and largely observational. Sanctuary Tulum does not present these protocols as cures or guaranteed treatments, and no diagnostic or prognostic claim is made outside a clinical evaluation.
Integration and Aftercare
A stay is only useful if it holds. Every program ends with a written integration and aftercare plan — continued check-ins with the integration team, referral to trauma-informed practitioners at home when appropriate, and lifestyle protocols covering nutrition, sleep, movement, and nervous-system regulation. Guests are encouraged to maintain their existing relationship with a treating physician and to return for booster sessions when a specific life transition benefits from it.
References
- Padmanabhan A, et al. "Guidelines on the Use of Therapeutic Apheresis in Clinical Practice." J Clin Apher. 2019;34(3):171-354.
- Elvis AM, Ekta JS. "Ozone therapy: A clinical review." J Nat Sci Biol Med. 2011;2(1):66-70.
- Reeves HM, Winters JL. "The mechanisms of action of plasma exchange." Br J Haematol. 2014;164(3):342-351.









